Mice exhibited a greater survival rate following CSP2-E1Ad10 treatment compared with the negative control vehicle (PBS), highlighting the potential of CSP2-E1Ad10 in reducing pneumococcal infections caused by group 2 pneumococcus [64]. This evidence concerns the gene CSP2 and pneumococcal infection.